Year: 2019
BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018
February 12, 2019
Important progress made in 2018: PoC for bemcentinib reported in multiple cancer indications AML/MDS and…
Read More
BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presentation and Webcast
February 5, 2019
Bergen, Norway, 05 February 2019 - BerGenBio ASA (OSE:BGBIO), will announce its results for the…
Read More
BerGenBio announces start of phase I trial evaluating ADCT-601, a novel anti-AXL ADC, in patients with advanced solid tumours
January 21, 2019
ADCT-601 uses a proprietary AXL antibody developed by BerGenBio and licensed to ADC Therapeutics for…
Read More
BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149
January 9, 2019
BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development BGB149 is BerGenBio’s…
Read More
BerGenBio to present company overview at Biotech Showcase 2019 during annual J.P. Morgan Conference in San Francisco
January 8, 2019
Bergen, Norway, Jan 8th 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on…
Read More
BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in high-risk MDS
January 4, 2019
Phase II monotherapy study of bemcentinib in high-risk MDS & AML Will enrol up to…
Read More
